CAR T cell entry into tumor islets is a two-step process dependent on IFNγ and ICAM-1
C. Kantari-Mimoun, S. Barrin, S. Haghiri, C. Gervais, J. Mittelstaet, N. Mockel-Tenbrinck, A. Kinkhabwala, D. Damotte, A. Lupo, M. Sibony, M. Alifano, L. Vimeux, E. Dondi, N. Bercovici, A. Trautmann, A. Kaiser, E. Donnadieu
Abstract
Adoptive transfer of T cells expressing chimeric antigen receptors (CARs) has shown remarkable clinical efficacy against advanced B cell malignancies but not yet against solid tumors. Here, we used fluorescent imaging microscopy and ex vivo assays to compare the early functional responses (migration, Ca2+ and cytotoxicity) of CD20 and EGFR CAR T cells upon contact with malignant B and carcinoma cells. Our results indicate that CD20 CAR T cells rapidly form productive ICAM-1-dependent conjugates with their targets. By comparison, EGFR CAR T cells only interact at first with a subset of carcinoma cells located at the periphery of tumor islets. After this initial peripheral activation, EGFR CAR T cells progressively infiltrate the center of tumor cell regions. The analysis of this two-step entry process shows that activated CAR T cells trigger the upregulation of ICAM-1 on tumor cells in an IFN{gamma}-dependent pathway. The blockade of ICAM-1/LFA-1 interactions prevents CAR T cell recruitment into tumor islets. The requirement for IFN{gamma} and ICAM-1 to enable CAR T cell entry into tumor islets is of significance for improving CAR T strategy in solid tumors.
02 /Specification & Classification
Click any tag to browse matching papersReproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Solid tumor CAR T cells engineered with fusion proteins targeting PDL1 for localized IL-12 delivery
John Paul Murad, Lea Christian, … Saul J. Priceman·bioRxiv·Apr 4, 2025
- Universal chimeric Fcγ receptor T cells with appropriate affinity for IgG1 antibody exhibit optimal antitumor efficacy
- Antigen-dependent IL-12 signaling in CAR T cells promotes regional to systemic disease targeting
E. Lee, C. Cullen, … S. J. Priceman·bioRxiv·Jan 6, 2023
- CAR-MACROPHAGES ACTIVATE ANTI TUMOR T CELLS IN THE ABSENCE OF PHAGOCYTOSIS
Lea C. Feldmann, Amaury Vaysse, … Capucine L. Grandjean·bioRxiv·Aug 28, 2026
- CAR T cell cytotoxic responses are rapidly generated and sensitive to the unligated TCR
Kevin L. Scrudders, Suriya Selvarajan, … Shalini T. Low-Nam·bioRxiv·Jul 25, 2025
- PD-L1 blockade restores CAR T cell activity through IFNγ-regulation of CD163+ macrophages
Y. Yamaguchi, J. Gibson, … S. J. Priceman·bioRxiv·Jan 25, 2022